UroGen Pharma Ltd. (URGN) Stock Forecast
URGN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.62 / 5 from 8 analysts
- Price target
- $60.00 average of analyst targets
- Upside to target
- +73.6% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.38
- 52-week range
- $17.00 – $50.29
URGN analyst ratings
8 analystsNumber of analysts at each rating.
URGN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
URGN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.09 | −$0.07 | $0.19 | −$0.69 | +113.2% | 7 |
| Current fiscal year (2026) | −$0.24 | −$0.83 | $0.20 | −$3.19 | +92.4% | 7 |
| Next fiscal year (2027) | $2.59 | $1.05 | $5.19 | −$0.24 | +1,165.3% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
URGN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $90.6M | $84.1M | $95.5M | +229.6% | 8 |
| Current fiscal year (2026) | $322.2M | $302.0M | $336.2M | +193.5% | 8 |
| Next fiscal year (2027) | $531.6M | $462.9M | $648.8M | +65.0% | 8 |
URGN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
URGN revenue: reported and forecast
URGN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | $0.09 | $0.09 | $0.09 | $0.09 | −196.2% | 5 up · 0 down |
| Current fiscal year (2026) | −$0.84 | −$0.24 | −$0.24 | −$0.24 | −$0.24 | −71.3% | 5 up · 0 down |
| Next fiscal year (2027) | $1.23 | $2.79 | $2.79 | $2.79 | $2.59 | +110.3% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
URGN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; URGN beat in 4 of 12.
What analysts expect from URGN
8 analysts cover UroGen Pharma; their consensus rating is strong buy (4.62 on a 1–5 scale, where 5 is a strong buy). The average price target is $60.00, 73.6% above the latest close of $34.56. Analysts expect earnings of −$0.24 per share for 2026, +92.4% from a year earlier. For 2027 the average estimate is $2.59 per share on revenue of $531.6 million. UroGen Pharma beat the EPS estimate in 4 of the last 12 quarters.
Related: URGN income statement, URGN key metrics, URGN chart. See the URGN stock overview for the latest quote and news.
URGN forecast FAQ
What is UroGen Pharma's price target?
The average analyst price target for UroGen Pharma is $60.00, 73.6% above the latest close of $34.56.
Is UroGen Pharma a buy, hold or sell?
Of 8 analysts covering UroGen Pharma, 6 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is UroGen Pharma's EPS forecast?
Analysts forecast −$0.24 per share for 2026 (range −$0.83 to $0.20); for 2027 the estimate is $2.59.
What is UroGen Pharma's revenue forecast?
The average revenue estimate for 2026 is $322.2 million, growth of 193.5%; for 2027 it is $531.6 million.
When does UroGen Pharma report earnings?
UroGen Pharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $0.38.
Does UroGen Pharma usually beat earnings estimates?
UroGen Pharma reported EPS at or above the analyst estimate in 4 of the last 12 quarters.